Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.
about
Probiotics--interactions with bile acids and impact on cholesterol metabolism.Gut microbiota and probiotics: Focus on diabetes mellitus.A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.Advanced bile acid-based multi-compartmental microencapsulated pancreatic β-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells.The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus.Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.Effects of Enterococcus faecium M 74 strain on selected blood and production parameters of laying hens.Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic β cells.The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
P2860
Q38051231-147F3DED-84BD-4A09-AD27-E937B0C9EA92Q38616155-9077B799-CACF-4C2D-A2A2-0A42DE5DF39FQ38816417-BEAA8B9B-72CE-464D-8F00-0EE0FC468107Q38834909-0896D488-24D4-4E0E-A617-6E0F0747D11BQ38846334-2F840631-9CE4-4E48-B7D4-F36FD32F7E98Q38943790-CA568CA2-2204-4EDF-95A7-70E3ED39DF45Q38976374-A992B919-9CFE-4D60-BD31-4408C416684BQ39321884-A8701E5E-31C2-4C1F-B24F-642C201CDB3CQ39351329-4AC4C349-D71F-4A5A-A217-E3E91198D4C2Q40509847-6330F273-B96E-4D40-9051-85C0C3AC724FQ42770089-1ACB439A-B095-415F-B40A-97E06AA706BBQ42832226-46FEBDEB-8071-4BC1-A1A0-7599F3EDB780Q42921986-9D864A54-FE82-4872-BCFA-04C9630DF9B8Q42935253-CA12F7D7-C0E6-488B-B208-E26082EFD43BQ43808142-524896A2-737D-47F4-B6E4-ABCF48D3B591Q46000543-836BD96C-5B2F-4B26-9D74-81013AA22134Q46382050-63D9B0D6-AA5D-456A-BC48-84A8DE39B1B7Q48089000-B7754B7A-541F-427B-A007-0D944D557BE2Q48177243-5838F0B9-B81A-41A3-9784-3B9160971D35Q48291159-CB459E8A-C0A3-4D0E-8112-89C69B5EC4BDQ49853243-A75C8765-70F5-4FA3-BBF2-58F8B688857DQ51833733-00BFAE20-371A-4C72-8B5F-A09701AB454DQ53281341-1CF1040F-05BE-4752-943A-5D460BBDAE84Q57148084-1BF5F179-F3D5-4966-AFAE-29E7989FFE57
P2860
Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Influence of the semisynthetic ...... rats treated with probiotics.
@en
Influence of the semisynthetic ...... rats treated with probiotics.
@nl
type
label
Influence of the semisynthetic ...... rats treated with probiotics.
@en
Influence of the semisynthetic ...... rats treated with probiotics.
@nl
prefLabel
Influence of the semisynthetic ...... rats treated with probiotics.
@en
Influence of the semisynthetic ...... rats treated with probiotics.
@nl
P50
P1476
Influence of the semisynthetic ...... c rats treated with probiotics
@en
P304
P356
10.1358/MF.2008.30.2.1159652
P577
2008-03-01T00:00:00Z